Brolucizumab-key learnings from HAWK and HARRIER.
作者信息
Sharma Ashish, Parachuri Nikulaa, Kumar Nilesh, Sharma Rohini, Bandello Francesco, Kuppermann Baruch D, Loewenstein Anat
机构信息
Lotus Eye Hospital and Institute, Avinashi Road, Coimbatore, TN, India.
Department of Healthcare, The TIPS Global Institute, Coimbatore, Tamil Nadu, India.
出版信息
Eye (Lond). 2020 Aug;34(8):1318-1320. doi: 10.1038/s41433-020-0842-z. Epub 2020 Mar 13.
Abstract
摘要
相似文献
1
Brolucizumab-key learnings from HAWK and HARRIER.
Eye (Lond). 2020 Aug;34(8):1318-1320. doi: 10.1038/s41433-020-0842-z. Epub 2020 Mar 13.
2
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Ophthalmology. 2020 Jan;127(1):72-84. doi: 10.1016/j.ophtha.2019.04.017. Epub 2019 Apr 12.
3
Re: Dugel et al: HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration (Ophthalmology. 2019 Apr 12 [Epub ahead of print]).
Ophthalmology. 2019 Dec;126(12):e95-e96. doi: 10.1016/j.ophtha.2019.08.017.
4
Re: Monés et al.: Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER (Ophthalmology. 2021;128:1050-1059).
Ophthalmology. 2021 Sep;128(9):e47. doi: 10.1016/j.ophtha.2021.04.029. Epub 2021 May 28.
5
Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration.
Ophthalmology. 2020 Jul;127(7):963-976. doi: 10.1016/j.ophtha.2019.12.031. Epub 2020 Jan 17.
6
Brolucizumab: First Approval.
Drugs. 2019 Dec;79(18):1997-2000. doi: 10.1007/s40265-019-01231-9.
7
Brolucizumab and immunogenicity.
Eye (Lond). 2020 Oct;34(10):1726-1728. doi: 10.1038/s41433-020-0853-9. Epub 2020 Apr 6.
8
Reply to Comment on: Is this a 737 Max Moment for Brolucizumab?
Am J Ophthalmol. 2021 Mar;223:446-447. doi: 10.1016/j.ajo.2020.06.034. Epub 2020 Nov 10.
9
Immediate onset of sterile endophthalmitis with hypopyon after intravitreal Brolucizumab in a case of polypoidal choroidal vasculopathy.
Indian J Ophthalmol. 2021 Feb;69(2):469-470. doi: 10.4103/ijo.IJO_3436_20.
10
[Bilateral vasculitis following intravitreal brolucizumab injection].
Ophthalmologe. 2022 Jan;119(Suppl 1):93-97. doi: 10.1007/s00347-021-01330-7. Epub 2021 Feb 17.
引用本文的文献
1
Brolucizumab for the Treatment of Degenerative Macular Conditions: A Review of Clinical Studies.
Drug Des Devel Ther. 2022 Aug 9;16:2659-2680. doi: 10.2147/DDDT.S378450. eCollection 2022.
2
Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice.
Front Pharmacol. 2021 Nov 4;12:720345. doi: 10.3389/fphar.2021.720345. eCollection 2021.
Zotero 插件